Noile-Immune Biotech Inc.

4893 TSE Pharmaceutical PHARMACEUTICAL

Key Metrics

Market Cap

6.6B ($41.3M)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

N/A

Net Income

-964.5M

Gross Margin

N/A

Op. Margin

N/A

Net Margin

N/A

ROE

-20.4%

ROA

-20.1%

D/E

0.02

Dividend Yield

N/A

EPS

-22.28

Current Ratio

68.77

Price History

Company Info

Industry	PHARMACEUTICAL
Market Segment	Growth
Accounting	Japan GAAP
Currency	JPY
Fiscal Year	2024

Business Overview

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, an autologous CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.

Full Financials Advanced Charts Filings

Peers

Takeda Pharmaceutical Company Limited

4502

9.1T

P/E: 81.3

Astellas Pharma Inc.

4503

4.3T

P/E: 34.2

Shionogi & Co.,Ltd.

4507

2.9T

P/E: 16.8

Kyowa Kirin Co.,Ltd.

4151

1.2T

P/E: 18.3

Sumitomo Pharma Co.,Ltd.

4506

736.8B

P/E: 4.8

SANTEN PHARMACEUTICAL CO.,LTD.

4536

542.5B

P/E: 18.2

Nippon Shinyaku Co.,Ltd.

4516

337.9B

P/E: 10.6

GNI Group Ltd.

2160

158.0B

P/E: --

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About Noile-Immune Biotech Inc.

Ticker	4893
Exchange	TSE
Sector	Pharmaceutical
Industry	PHARMACEUTICAL